Cargando…

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups

Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have become available as an alternative to warfarin anticoagulation in non-valvular atrial fibrillation (NVAF). Methods. MEDLINE and CENTRAL, regulatory agencies websites, clinical trials registers and conference proceedin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gómez-Outes, Antonio, Terleira-Fernández, Ana Isabel, Calvo-Rojas, Gonzalo, Suárez-Gea, M. Luisa, Vargas-Castrillón, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885278/ https://www.ncbi.nlm.nih.gov/pubmed/24455237 http://dx.doi.org/10.1155/2013/640723

Ejemplares similares

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
por: Gómez-Outes, Antonio, et al.
Publicado: (2012)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
por: Li, Hongxia, et al.
Publicado: (2021)

Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
por: Rutherford, Ole-Christian W, et al.
Publicado: (2020)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review
por: Gómez-Outes, Antonio, et al.
Publicado: (2014)

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
por: Koretsune, Yukihiro, et al.
Publicado: (2017)

Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
por: Alberts, Mark J., et al.
Publicado: (2022)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?
por: Silva, Vanessa M., et al.
Publicado: (2019)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
por: Lip, Gregory Y. H., et al.
Publicado: (2016)

A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation
por: Hill, Nathan R., et al.
Publicado: (2020)

Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin
por: Watanabe, Tetsuya, et al.
Publicado: (2016)

Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
por: Miwa, Yosuke, et al.
Publicado: (2016)

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban
por: Winkle, Roger A., et al.
Publicado: (2014)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Apixaban in Comparison to Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
por: Siddiqui, Muhammad U., et al.
Publicado: (2019)

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
por: Wanat, Matthew A., et al.
Publicado: (2019)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes
por: Weir, Matthew R., et al.
Publicado: (2021)

Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
por: Sood, Nitesh, et al.
Publicado: (2023)

Appropriateness of rivaroxaban and apixaban dosing in hospitalized patients with a newly diagnosed nonvalvular atrial fibrillation at a single tertiary hospital
por: Alshibani, Mohannad
Publicado: (2023)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ac59fhu8aqif4ft6faut23mdri